Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy

Details 詳細情報について

• CRID

  1361699995822580864

• DOI

  10.1007/s00520-009-0737-9

• ISSN

  14337339

  09414355

• Web Site

  http://link.springer.com/content/pdf/10.1007/s00520-009-0737-9.pdf

  http://link.springer.com/article/10.1007/s00520-009-0737-9/fulltext.html

  http://link.springer.com/content/pdf/10.1007/s00520-009-0737-9

• Data Source

  • Crossref